Premium
Fanconi Syndrome Secondary to Deferasirox in Diamond–Blackfan Anemia: Case Series and Recommendations for Early Diagnosis
Author(s) -
Papneja Koyelle,
Bhatt Mihir D.,
KirbyAllen Melanie,
Arora Steven,
Wiernikowski John T.,
Athale Uma H.
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25995
Subject(s) - deferasirox , medicine , fanconi syndrome , fanconi anemia , context (archaeology) , pediatrics , chelation therapy , anemia , myelodysplastic syndromes , intensive care medicine , thalassemia , bone marrow , kidney , paleontology , biochemistry , chemistry , biology , dna repair , gene
Deferasirox is an oral iron chelator used to treat patients with transfusion‐related iron overload. We report, from two institutions, two children with Diamond–Blackfan anemia who developed Fanconi syndrome secondary to deferasirox administration, along with a review of the literature. The current recommendation for the laboratory monitoring of patients receiving deferasirox does not include serum electrolytes or urine analysis. Thus, despite routine clinic visits and bloodwork, these two patients presented with life‐threatening electrolyte abnormalities requiring hospitalization. Hence, we propose the inclusion of serum electrolytes and urine analysis as part of routine monitoring to facilitate the early diagnosis of Fanconi syndrome in the context of high doses of deferasirox therapy.